An emerging pharmaceutical manufacturer was preparing to launch its first commercial product, which would be the first new brand drug for a specific indication in 20 years. The client was looking for assistance with trade/distribution.

The Two Labs team developed and executed a full Commercialization strategy that included not just Product Launch, ASL and Trade Management, but also EHRx and Compendia, as we saw an opportunity to create a new drug classification for this product.

A leading manufacturer in the cannabis space wanted to introduce a first in class cannabinoid treatment to be used for seizures.

Two Labs’ Compendia Team worked to develop the key components of the package insert, artwork files and dossier to shape the strategy and key clinical messages. We coordinated with internal stakeholders to ensure that the product messaging was in alignment with the Compendia data that is accessed by managed care organizations for reimbursement, EMRs for access and prescribing, as well as hospitals and key organizations that would treat patients who experience seizures.

A specialty biopharmaceutical company was launching a new product into a competitive space and needed to expedite visibility into EHR platforms to reach their sales goals.

The Two Labs team deployed our iOS App model to their sales representatives to address the product visibility issues at the HCP level. The app assisted HCPs with system updates and manual additions, which expedited the electronic prescribing process. In addition, Two Labs provided the steps to set the new product as a favorite within the HCPs EHR system, differentiating it from competitors and streamlining the prescribing process.

An emerging biotech company was preparing to launch its first product in the neurology space and, because they had an underdeveloped staff, needed help with pricing and managed care strategies.

Two Labs’ Market Access team developed a pricing and managed care strategy by analyzing the disease state using secondary data, researching analogues to optimize the launch, and combining payer, physician and patient research. The team also developed a strategy for if, how, and when to contact select payers.

An established and well-known pharmaceutical manufacturer with multiple commercialized products in the market wanted to launch a new generic business entity within a tight timeline, making it difficult to achieve licensing on time.

Our PharmaLicense team developed a licensing strategy to add the generic entity as a DBA/trade name to the client’s current licenses. Two Labs engaged directly with state regulators in a timely fashion to identify and file the necessary documentation and mitigate any concerns.

An emerging pharma company was launching two products and they needed help developing a comprehensive path to help them get from clinical to commercial.

Two Labs partnered with the company and supported them with our entire suite of services: Channel Strategy and Implementation, Compendia, EHRx, Trade, and Licensing.

A leading manufacturer of dermatology products was going through a product acquisition and during the transition was concerned with inventory being correctly accounted for according to the terms agreed upon by all parties in the acquisition.

The Two Labs Trade team utilized our unique understanding of channel data to find $4 million of inventory that was not being accounted for, the liabilities of which should have been the responsibility of the large multi-national pharma company who was selling the product. The situation required a deep understanding of trade, distribution, finance and data. It was necessary for us to show where the error was made and how it was overlooked.